Published by Global Banking & Finance Review®
Posted on January 20, 2026
1 min readLast updated: January 20, 2026
Add as preferred source on GoogleGenentech is doubling its investment in a North Carolina facility to $2 billion, creating over 2,000 jobs and enhancing biomanufacturing capacity.
Jan 20 (Reuters) - Roche's Genentech said on Tuesday it will more than double its initial investment in a biomanufacturing facility in North Carolina to about $2 billion, as the companies look to further boost their $50 billion investment in the U.S.
The facility, based in Holly Springs, North Carolina is set to be operational by 2029 and will produce next-generation treatments for metabolic conditions, such as obesity.
The investment is expected to support more than 2,000 jobs, which includes 500 high-wage manufacturing jobs and 1,500 construction jobs, Genentech said, adding that the expansion will further raise production volumes and scale manufacturing capacity within the facility.
In May last year, Genentech invested over $700 million in the North Carolina facility, as it looked to expand its presence in the United States amid President Donald Trump's push for pharma companies to onshore domestic manufacturing to the U.S.
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Shailesh Kuber)
Job creation refers to the process of providing new employment opportunities, often as a result of business expansion or economic growth.
Economic impact measures the effect of an event, policy, or investment on the economy, including changes in employment, income, and overall economic activity.
Investment is the allocation of resources, usually money, in order to generate income or profit. It can take many forms, including stocks, bonds, and real estate.
Explore more articles in the Finance category
